102 research outputs found

    A Metabolomic Analysis Of Thiol Response For Standard And Modified N-Acetyl Cysteine Treatment Regimens In Patients With Acetaminophen Overdose

    Get PDF
    Abstract Nā€acetylcysteine (NAC) is an antidote to prevent acetaminophen (paracetamolā€APAP)ā€induced acute liver injury (ALI). The 3ā€bag licensed 20.25Ā h standard regimen, and a 12Ā h modified regimen, are used to treat APAP overdose. This study evaluated the redox thiol response and APAP metabolites, in patients with a single APAP overdose treated with either the 20.25Ā h standard or 12Ā h modified regimen. We used liquid chromatography tandem mass spectrometry to quantify clinically important oxidative stress biomarkers and APAP metabolites in plasma samples from 45 patients who participated in a randomized controlled trial (SNAP trial). We investigated the time course response of plasma metabolites at predose, 12Ā h, and 20.25Ā h postā€start of NAC infusion. The results showed that the 12Ā h modified regimen resulted in a significant elevation of plasma NAC and cysteine concentrations at 12Ā h postā€infusion. We found no significant alteration in the metabolism of APAP, mitochondrial, amino acids, and other thiol biomarkers with the two regimens. We examined APAP and purine metabolism in overdose patients who developed ALI. We showed the major APAPā€metabolites and xanthine were significantly higher in patients with ALI. These biomarkers correlated well with alanine aminotransferase activity at admission. Receiver operating characteristic analysis showed that at admission, plasma APAPā€metabolites and xanthine concentrations were predictive for ALI. In conclusion, a significantly higher redox thiol response with the modified NAC regimen at 12Ā h postdose suggests this regimen may produce greater antioxidant efficacy. At baseline, plasma APAP and purine metabolites may be useful biomarkers for early prediction of APAPā€induced ALI

    Mitochondrial respiration - an important therapeutic target in melanoma

    Get PDF
    The importance of mitochondria as oxygen sensors as well as producers of ATP and reactive oxygen species (ROS) has recently become a focal point of cancer research. However, in the case of melanoma, little information is available to what extent cellular bioenergetics processes contribute to the progression of the disease and related to it, whether oxidative phosphorylation (OXPHOS) has a prominent role in advanced melanoma. In this study we demonstrate that compared to melanocytes, metastatic melanoma cells have elevated levels of OXPHOS. Furthermore, treating metastatic melanoma cells with the drug, Elesclomol, which induces cancer cell apoptosis through oxidative stress, we document by way of stable isotope labeling with amino acids in cell culture (SILAC) that proteins participating in OXPHOS are downregulated. We also provide evidence that melanoma cells with high levels of glycolysis are more resistant to Elesclomol. We further show that Elesclomol upregulates hypoxia inducible factor 1-Ī± (HIF-1Ī±), and that prolonged exposure of melanoma cells to this drug leads to selection of melanoma cells with high levels of glycolysis. Taken together, our findings suggest that molecular targeting of OXPHOS may have efficacy for advanced melanoma. Ā© 2012 Barbi de Moura et al

    PKCĪ± tumor suppression in the intestine is associated with transcriptional and translational inhibition of cyclin D1

    Get PDF
    Alterations in PKC isozyme expression and aberrant induction of cyclin D1 are early events in intestinal tumorigenesis. Previous studies have identified cyclin D1 as a major target in the antiproliferative effects of PKCĪ± in non-transformed intestinal cells; however, a link between PKC signaling and cyclin D1 in colon cancer remained to be established. The current study further characterized PKC isozyme expression in intestinal neoplasms and explored the consequences of restoring PKCĪ± or PKCĪ“ in a panel of colon carcinoma cell lines. Consistent with patterns of PKC expression in primary tumors, PKCĪ± and Ī“ levels were generally reduced in colon carcinoma cell lines, PKCĪ²II was elevated and PKCĪµ showed variable expression, thus establishing the suitability of these models for analysis of PKC signaling. While colon cancer cells were insensitive to the effects of PKC agonists on cyclin D1 levels, restoration of PKCĪ± downregulated cyclin D1 by two independent mechanisms. PKCĪ± expression consistently (a) reduced steady-state levels of cyclin D1 by a novel transcriptional mechanism not previously seen in non-transformed cells, and (b) re-established the ability of PKC agonists to activate the translational repressor 4E-BP1 and inhibit cyclin D1 translation. In contrast, PKCĪ“ had modest and variable effects on cyclin D1 steady state levels and failed to restore responsiveness to PKC agonists. Notably, PKCĪ± expression blocked anchorage-independent growth in colon cancer cells via a mechanism partially dependent on cyclin D1 deficiency, while PKCĪ“ had only minor effects. Loss of PKCĪ± and effects of its re-expression were independent of the status of the APC/Ī²-catenin signaling pathway or known genetic alterations, indicating that they are a general characteristic of colon tumors. Thus, PKCĪ± is a potent negative regulator of cyclin D1 expression and anchorage-independent cell growth in colon tumor cells, findings that offer important perspectives on the frequent loss of this isozyme during intestinal carcinogenesis

    Radio Astronomy

    Get PDF
    Contains table of contents and reports on seven research projects.National Science Foundation (Grant AST 86-17172)National Aeronautics and Space AdministrationJet Propulsion LaboratoryNASA/Goddard Space Flight Center (Grant NAG5-10)SM Systems and Research, Inc.U.S. Navy Office of Naval Research (Contract N00014-86-C-2114)Center for Advanced Television StudiesNASA/Goddard Space Flight Center (Grant NAG5-537

    Radio Astronomy

    Get PDF
    Contains table of contents for Section 4 and reports on twelve research projects.National Science Foundation Grant AST 88-19848Jet Propulsion Laboratory Contract 957687National Aeronautics and Space Administration Grant NAGW 1386National Science Foundation Grant AST 88-19848Annie Jump Cannon AwardSM Systems and Research, Inc.U.S. Navy Office of Naval Research Contract N00014-88-K-2016NASA/Goddard Space Flight Center Grant NAG 5-537NASA/Goddard Space Flight Center Grant NAG 5-10Woods Hole Oceanographic Institution Contract SC-28860Leaders for Manufacturing Progra
    • ā€¦
    corecore